The initial reporter received negative elecsys anti-sars-cov-2 results for one patient tested on a cobas 8000 e 602 module serial number (b)(4).The patient was previously tested with an unknown pcr methodology.The first positive pcr result was performed on (b)(6) 2020.All of the patient samples were tested with menarini covid-19 igg/igm rapid test cassette.Some samples were tested with antibody assays biozek medical covid-19 igg/igm rapid test, innovita 2019-ncov ab test, wondfo sars-cov-2 antibody test, and abbott sars-cov-2 igg assay.The menarini, biozek, innovita, and wondfo antibody assays are not eua approved.
|
The customer's calibration and qc data provided were ok.The customer provided the patient's sample for investigation.The investigation confirmed the customer's elecsys anti-sars-cov-2 result, 0.550 non-reactive.The patient's result of 0.550 coi showed a very weak reaction, but it is distinguishable from negative samples ((b)(4) measurements show a coi of 0.2 or less).Tested with creative diagnostics covid19 test igg/igm rapid test, the patient had a reactive igg and igm result.Tested with an independent roche internal research in-house sars-cov2 antibody assay, the patient had a reactive result.Per product labeling, "a negative test result does not rule out the possibility of an infection with sars-cov-2.Serum or plasma samples from the early (pre-seroconversion) phase of illness can yield negative findings.Therefore, this test cannot be used to diagnose an acute infection.Also, over time, titers may decline and eventually become negative." further clarification of the observed discrepancies is not possible with available methods and the current state of the art based on the available data, a general product problem is excluded.The investigation did not identify a product problem.The cause of the event could not be determined.
|